Novo Nordisk A/S (NVO)
46.94
+0.20
(+0.44%)
USD |
NYSE |
Aug 24, 16:00
47.05
+0.10
(+0.22%)
After-Hours: 20:00
Novo Nordisk Price to Book Value : 6.132 for Aug. 24, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 6.105 |
| August 20, 2026 | 6.027 |
| August 19, 2026 | 6.071 |
| August 18, 2026 | 5.971 |
| August 17, 2026 | 5.862 |
| August 14, 2026 | 5.994 |
| August 13, 2026 | 6.102 |
| August 12, 2026 | 6.059 |
| August 11, 2026 | 6.161 |
| August 10, 2026 | 6.234 |
| August 07, 2026 | 6.173 |
| August 06, 2026 | 6.004 |
| August 05, 2026 | 5.816 |
| August 04, 2026 | 5.784 |
| August 03, 2026 | 6.151 |
| July 31, 2026 | 6.150 |
| July 30, 2026 | 6.741 |
| July 29, 2026 | 6.737 |
| July 28, 2026 | 6.656 |
| July 27, 2026 | 6.488 |
| July 24, 2026 | 6.370 |
| July 23, 2026 | 6.293 |
| July 22, 2026 | 6.294 |
| July 21, 2026 | 6.450 |
| July 20, 2026 | 6.48 |
| Date | Value |
|---|---|
| July 17, 2026 | 6.573 |
| July 16, 2026 | 6.724 |
| July 15, 2026 | 6.604 |
| July 14, 2026 | 6.410 |
| July 13, 2026 | 6.437 |
| July 10, 2026 | 6.463 |
| July 09, 2026 | 6.385 |
| July 08, 2026 | 6.386 |
| July 07, 2026 | 6.484 |
| July 06, 2026 | 6.434 |
| July 02, 2026 | 6.587 |
| July 01, 2026 | 6.370 |
| June 30, 2026 | 6.262 |
| June 29, 2026 | 6.861 |
| June 26, 2026 | 6.823 |
| June 25, 2026 | 6.762 |
| June 24, 2026 | 6.729 |
| June 23, 2026 | 6.730 |
| June 22, 2026 | 6.512 |
| June 18, 2026 | 6.13 |
| June 17, 2026 | 6.177 |
| June 16, 2026 | 6.181 |
| June 15, 2026 | 6.234 |
| June 12, 2026 | 6.228 |
| June 11, 2026 | 6.239 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| AstraZeneca PLC | 10.93 |
| Johnson & Johnson | 7.739 |
| Eli Lilly & Co. | 34.67 |
| Merck & Co., Inc. | 8.873 |
| Novartis AG | 6.962 |
Price to Book Value Related Metrics
| PE Ratio | 11.47 |
| PS Ratio | 4.056 |
| PEG Ratio | 0.9105 |
| Price to Free Cash Flow | 27.76 |
| Price | 46.94 |
| Earnings Yield | 8.72% |
| Market Cap | 157.07B |
| PEGY Ratio | 0.6977 |
| Operating PE Ratio | 8.939 |
| Normalized PE Ratio | 11.03 |